John Hall, MD
Dermatology · Greensboro, NCNPI 1174610935
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $466 of the $653 with a category attached, or 71.3%. 12 manufacturers reported payments, led by Lilly USA, LLC at 30.7% of the total. Reporting peaked in 2023 at $213 and has fallen 63.1% since, to $79 in 2025. That places this record below the midpoint for dermatology clinicians in NC, where the typical reported total is $2,057.
Across 30 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$200
- Johnson & Johnson$172
- Esperion Therapeutics, Inc.$42
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
- Vanda Pharmaceuticals Inc.$36
- Pfizer$30
- plus $132 from 6 others
What the payments were for
- Food & beverage$46671%
- Education$18729%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $200 |
| Johnson & Johnson | 2 | $172 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Pfizer | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| GSK | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
How this compares
$653 in reported general payments places this provider in the 30th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 48 | $232,325 |
| Humira(Cf) PenAdalimumab | 13 | $180,898 |
| Clobetasol Propionate | 389 | $11,990 |
| Fluticasone Propionate | 279 | $8,103 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 312 | $5,635 |
| Doxycycline Hyclate | 340 | $5,291 |
| Ketoconazole | 165 | $2,885 |
| Betamethasone Dipropionate | 58 | $2,730 |
| Metronidazole | 54 | $2,552 |
| Triamcinolone Acetonide | 126 | $2,102 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 23 | $1,566 |
| Desonide | 25 | $1,523 |
| Clindamycin Phosphate | 53 | $1,449 |
| ValacyclovirValacyclovir Hcl | 61 | $1,284 |
| Fluorouracil | 15 | $1,134 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Greensboro
- Jennifer DavidGreensboro$35K
- Arthur GrayGreensboro$18K
- Steven FeldmanWinston Salem$3.4M
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- George MagelHickory$554K
- Muneeb ShahClinton$451K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.